Form 4: Amicus Therapeutics Director Eiry Roberts Acquires Shares and Stock Options

Director Eiry Roberts acquired shares and stock options in Amicus Therapeutics, according to a recent SEC Form 4 filing.

Summary

• On June 6, 2024, Eiry Roberts, a director of Amicus Therapeutics, acquired 11,847 shares of common stock.
• These shares were acquired at a price of $0.0.
• Following the transaction, Roberts directly owns 55,861 shares of Amicus Therapeutics.
• Roberts also acquired 42,467 stock options with an exercise price of $10.27, which vest on June 6, 2025, and expire on June 6, 2034.
• These options are for Amicus common stock.
• The filing was signed by Christian Formica, Attorney-in-Fact, on June 7, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the RSUs and stock options in the future suggests an expectation of continued service by the director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates